prgn-3006
pgen therapeutics
['myeloid', 'leukemia', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'prgn-3006', '$pgen']
#ash22: precigen announces positive phase 1 dose escalation data for autologous prgn-3006 ultracar-t manufactured overnight for next day infusion in relapsed or refractory acute myeloid leukemia patients. view press release: $pgen #bloodcancers #aml 
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies.